Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057564 · ClinicalTrials.gov registry record · Phase 3
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
A Phase 3 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 470
- Enrollment target
NCT00057564 is a Phase 3 study that has completed, run by Celgene Corporation. The registered enrollment target is 470 participants.
The verdict
NCT00057564, a Phase 3 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 470 participants
- Enrollment target
Study Summary
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
Interventions
- DRUG A (Thalidomide + Dexamethasone)
- DRUG B (Placebo + Dexamethasone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2003-02 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057564
The ClinicalTrials.gov registry entry for NCT00057564 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which A (Thalidomide + Dexamethasone) is the first listed.
NCT00057564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057564 about?
NCT00057564 is a clinical study titled "A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma". To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
What is the current status of trial NCT00057564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 470 participants. The study started on 2003-02. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00057564?
The interventions under investigation include: A (Thalidomide + Dexamethasone) (DRUG), B (Placebo + Dexamethasone) (DRUG).
Who is sponsoring clinical trial NCT00057564?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.